Only insights from MammaPrint® + BluePrint® can confidently guide ten years of ESBC treatment planning.

AGENDIA
MAMMAPRINT+BLUEPRINT

Confidently and quickly establish a personalized treatment plan for your patients*, ranging from neoadjuvant chemotherapy decisions to extended endocrine therapy, by utilizing MammaPrint + BluePrint results obtained within six days.[1] †



Decision Types	Neoadjuvant chemotherapy [2] Adjuvant chemotherapy [3]	Endocrine therapy [4]	Extended endocrine therapy [5]

ESBC = Early-stage breast cancer
*Women 18 years or older with early-stage breast cancer
† Agendia is committed to delivering results in less than 10 business days, and results are provided within 6 business days for the majority of cases.

1 McKelley, et al. SABCS 2020.
2 Whitworth, et al (2022) Distinct Neoadjuvant Chemotherapy Response and 5-year outcome in patients with ER+, HER2- Breast Tumors That Reclassify as Basal-type by the 80-gene signature. BluePrint basal subtype predicts neoadjuvant therapy response in ~400 HR+HER2- patients across 8 arms in the I-SPY 2 TRIAL. Presentation, EORTC-NCI-AACR. Dublin, Ireland. November 2018. Whitworth, et al. SABCS 2020, Poster #PD9-01. Whitworth, P., et al. Ann Surg Oncol. 2017;24(3):669-675. Groenendijk, F, et al. NPJ Breast Cancer. 2019;5:15.
3 Lopes Cardozo at al (ASCO 2020), Piccart et al (Lancet Oncol 2021), Lopes Cardozo, J., et al JCO 2022. 70-gene signature as an aid for treatment decisions in early breast cancer: Updated results of the phase three randomized MINDACT trial with an exploratory analysis by age. Prof Martine Piccart, MD et al. The Lancet Oncology 22, no. 4. March 12, 2021. 476-488. https://doi.org/10.1016/S1470-2045(21)00007-3
4 Use of Molecular Tools to Identify Patients with Indolent Breast Cancers with Ultralow Risk Over 2 Decades. Laura J. Esserman, MD, MBA et al. JAMA Oncology 3, no. 11. June 29, 2017. 1503–1510. https://doi.org/10.1001/jamaoncol.2017.1261
5 Utility of the 70-gene MammaPrint assay for prediction of benefit from extended letrozole therapy (ELT) in the NRG Oncology/NSABP B-42 trial. Priya Rastogi et al. Abstract, Journal of Clinical Oncology 39 no. 15. May 20, 2021. 502-502. https://doi.org/10.1200/JCO.2021.39.15_suppl.50

Results should be taken in the context of other relevant clinico-pathological factors and standard practice of medicine.

Functional Genomic Profiling with MammaPrint® + BluePrint®

With the combined insights of MammaPrint + BluePrint alongside clinical factors, physicians gain a more comprehensive basis for predicting prognosis and the benefit of specific treatments.

AGENDIA®
MAMMAPRINT

Learn the likelihood of a patient's breast cancer recurring.

+

AGENDIA®
BLUEPRINT

Determine the underlying genomics driving the growth of a tumor.



BASAL-TYPE	HER2-TYPE	LUMINAL-TYPE
High Risk Basal-type (ER-)	Low Risk HER2-type	Low Risk Luminal-type A
High Risk Basal-type (ER+)	High Risk HER2-type	UltraLow Risk Luminal-type A
		High Risk 1 Luminal-type B
		High Risk 2 Luminal-type B

A more complete understanding of each woman's breast cancer to enable optimized treatment planning.

SCAN TO LEARN MORE
OR ORDER A TEST

MKT-076-V2